Table 5. Hazards ratios for relapses (any localization, left; cardiac relapses, right) in cardiac sarcoidosis patients, according to immunosuppressive or immunomodulatory treatments.
| Treatment | All relapses /therapeutic sequences | HR (95%CI)‡ | P | Cardiac relapses /therapeutic sequences | HR (95%CI)‡ | P |
|---|---|---|---|---|---|---|
| None | 10/13 | 1 | - | 8/13 | 1 | - |
| Glucocorticoid alone | 17/77 | 0.51 (0.20–1.31) | 0.16 | 11/77 | 0.48 (0.18–1.31) | 0.15 |
| Methotrexate | 24/74 | 1.28 (0.43–3.75) | 0.66 | 9/74 | 0.62 (0.17–2.19) | 0.46 |
| Mycophenolic acid | 9/54 | 0.60 (0.21–1.69) | 0.33 | 5/54 | 0.47 (0.15–1.47) | 0.19 |
| Intravenous cyclophosphamide | 6/48 | 0.37 (0.13–1.08) | 0.069 | 2/48 | 0.16 (0.033–0.75) | 0.020 |
| Other* | 9/26 | 0.76 (0.22–2.61) | 0.67 | 5/26 | 0.48 (0.16–1.41) | 0.18 |
*Hydroxychloroquine alone (n = 16), infliximab (n = 4), azathioprine alone (n = 3), other immunosuppressant (n = 3)
†Analysis was performed including sequences of treatments between follow-up visits, excluding patients with a clinical therapeutic response as part of their diagnosis Birnie criteria and excluding periods of disease persistence.
‡ Analysis was adjusted on NYHA status (class 3–4 vs. 1–2), presence of cardiac rhythm disorders (yes vs. no), and presence of atrioventricular or ventricular conduction abnormalities (yes vs. no) during follow-up (time-dependent).